Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Así es como usted puede verificarlo

Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.

Los sitios web seguros .gov usan HTTPS
Un candado (  ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

La información sobre este estudio está en inglés.

Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.

Find more clinical trials

Sleep Therapy To Improve Cognition in People With Early-Stage Alzheimer's Disease

Start: August 12, 2021
End: June 2024
Enrollment: 40

What Is This Study About?

This study will evaluate the effects of a program that combines the use of bright light therapy with cognitive behavioral therapy for insomnia on sleep quality and cognitive function in people with mild cognitive impairment or early-stage Alzheimer's disease. Participants will be randomly assigned to either the study sleep program or placebo therapy sessions. All participants will wear a watch-like device that records information on sleep and activity for up to one year. Researchers will also measure changes in memory and cognitive function throughout the study.

Do I Qualify To Participate in This Study?

Minimum Age: 65 Years

Maximum Age: N/A

Must have:

  • Diagnosis of mild cognitive impairment or early-stage Alzheimer's Disease
  • Memory problems verified by a person who knows the participant well
  • Insomnia or a circadian rhythm disorder based on the International Classification of Sleep Disorders criteria or sleep problems due to excessive napping
  • Adequate vision and hearing to complete neuropsychological testing

Must NOT have:

  • MRI evidence of infection, blood clot, or other brain injuries in the past year that could contribute to neurological symptoms
  • Diagnosis of any major neurological disease other than probable mild Alzheimer's disease (e.g., Parkinson's disease, vascular dementia, multiple sclerosis, seizure disorder, Huntington's disease, brain tumor)
  • Any psychiatric condition within the past two years (e.g., major depression, bipolar disorder, schizophrenia, severe personality disorder)
  • Any uncontrolled medical condition or illness that could interfere with study procedures
  • Alcohol or substance abuse within the past two years
  • Sleep problems caused by a medical condition

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Yue Leng, PhD

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

California
UCSF
San Francisco, CA 94121
Recruiting
Bernard Landavazo, MA

Who Sponsors This Study?

Lead: University of California, San Francisco

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT03256539

alzheimers.gov/es

Un sitio web oficial del Gobierno de los Estados Unidos, gestionado por el Instituto Nacional sobre el Envejecimiento, parte de los Institutos Nacionales de la Salud